Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restem-X
- Development stage
- Preclinical
- Lead developer
- Restem Group
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Restem-X is an umbilical cord-derived mesenchymal progenitor cell (UMPC) therapy being developed by Restem for the treatment of osteoarthritis (OA). As a cell-based regenerative medicine, it utilizes the anti-inflammatory and tissue-reparative properties of mesenchymal progenitor cells to potentially address joint degeneration and associated pain. The therapy is designed to be administered locally to the affected joint to promote tissue repair and modulate the local immune environment. Restem-X is currently in the IND-enabling phase of development.
Beyond the preview
Go deeper on Restem-X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Restem-X.